Drugs / PRADUSINSTOBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05075993 | Nov 2021 → Feb 2027 expected | esophageal cancer, gastric cancer, head and neck carcinoma, hepatocellular carcinoma +4 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06159621 Comparator | Jul 2024 → Mar 2028 expected | head and neck squamous cell carcinoma | University of Pennsylvania | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRADUSINSTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314701 ↗ |
| Known as | LVGN3616 | “This will be a prospective, open-label, window of opportunity study of LVGN7409 and LVGN3616 (or nivolumab) in resectable HPV-negative HNSCC with co-primary endpoints of safety...” NCT06159621 ↗ |
| Action | Inhibit | “PD-1 inhibition (LVGN3616 or nivolumab)” NCT06159621 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314701 ↗ |